Before joining Second Sight Medical, Blake acted as finance senior VP at Tyr Pharma, and has held positions with Volcano Corp and BD Biosciences, the company said. Blake worked with Volcano during its $1.2 billion sale to Royal Philips (NYSE:PHG) in 2015, Second Sight added.
“We are delighted to welcome John to the Second Sight team. John’s financial acumen, track record of results and broad life sciences industry experience will support our efforts to grow Second Sight as we build on the momentum generated by the Argus II retinal prosthesis system and as we advance the development of the Orion cortical visual prosthesis system. In addition, John’s strengths and capabilities are well-known to me since we worked together at Volcano. It will be a genuine pleasure to work with him again,” prez & CEO Will McGuire said in a prepared statement.
“John’s appointment is further evidence that the leadership team at Second Sight continues to gain the depth that is critical to achieving the Company’s business objectives and building the commercial efforts for the Argus II and Orion,” chair Gregg Williams said in a prepared release.
“I am delighted to join Second Sight at this exciting time in its growth, build upon the commercial success to date of the Argus II and advance the development of Orion. I look forward to working with Will and the entire Second Sight team to impact the lives of patients, further accelerate our achievements and drive shareholder value,” CFO Blake said in a press release.
Former CFO Miller submitted his resignation last June, Second Sight said, but agreed to remain in the position until a replacement was named.
“We sincerely thank Tom for all of his many contributions to Second Sight. He was an integral part of Second Sight’s IPO process and has been a valued member of our management team. We wish him continued best in his future endeavors,” McGuire said in prepared remarks.
Innovatus Imaging said last week it named Xueli Wang as its new chief financial officer.
“We are energized to add Xueli’s broad business knowledge and analytical approach to our team as we continue to grow our business. His business acumen will further enhance our position as the preferred provider of best-in-class imaging devices and repair services,” prez & COO Bill Kollitz said in a prepared statement.
Trice Medical said last week it appointed current chief commercial officer Mark Foster as its new president, and that he will retain his position as CCO.
Prior to joining Trice Medical in 2016, Foster spent eight years with Smith & Nephew (NYSE:SNN), serving as U.S. sports medicine VP in his last position with the company. Foster also spent eight years with Boston Scientific (NYSE:BSX), the company reports.
“Mark has demonstrated tremendous leadership and management skills. Our board of directors admires his ability to execute and motivate teams to success. Mark will assume the role of president of the organization worldwide. I am looking forward to working with Mark to continue building the value of Trice Medical,” CEO Jeffrey O’Donnell, Sr. said in a prepared statement.
“I am honored and energized for the opportunity to further shape the direction of the organization. Trice has developed a dynamic imaging system that can deliver instant answers to patients, payors, and providers. It’s rare to find a platform that can bring value to all three of those stakeholders. The mi-eye two allows patients to get a dynamic evaluation of their knee or shoulder in an office setting, and to have their injections delivered under direct visualization, ensuring accurate placement. I’m looking forward to working with our team to find even more ways to deliver products that excite our customers,” Foster said in a press release.
Collagen Matrix said last week it tapped Gregory Pomrikas as its new research and development VP.
“We are pleased to add Greg to our team as we continue to drive product development across our portfolio. Greg’s experience and knowledge will strengthen our executive team and I look forward to expanding our product pipeline across the various technology platforms that underlie Collagen Matrix,” CEO Bart Doedens said in a prepared statement.
Asarpota is taking over accounting responsibilities from Jereme Sylvain, who NuVasive said served as principal accounting officer since August 2016.